5-amino-1mq vs nad+ Peptide Dosing Guide: Oral Protocol, Reconstitution & Safety (2026) For laboratory research use only. 5-Amino-1MQ 50mg Capsules | CAS

78 H 123 N 23 O 23 S 2 AOD-9604 Mechanism of Action Models the C-terminal lipolytic domain of human growth hormone (residues 176191) with an added N-terminal tyrosine

Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects

For this combination, track the following metrics weekly

The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problem